RxDoctor Payments Data

Anuradha Kantamani, MD

Internal Medicine · Katy, TXNPI 1649244054

Payments from drug & device makers

$871in general payments, 2019–2025

Across 24 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$500
  • AstraZeneca$120
  • Novo Nordisk$74
  • Lilly USA, LLC$38
  • GSK$31
  • Johnson & Johnson$29
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$871 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,805
Medicare patients
113
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin130$167,155
JanuviaSitagliptin Phosphate46$58,635
OzempicSemaglutide36$54,824
TrulicityDulaglutide12$22,340
XareltoRivaroxaban18$20,750
FarxigaDapagliflozin Propanediol12$12,890
Breo ElliptaFluticasone/Vilanterol12$7,150
PremarinEstrogens, Conjugated12$6,028
Combivent RespimatIpratropium/Albuterol Sulfate11$5,904
Insulin Lispro Kwikpen U-100Insulin Lispro19$4,136
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,903
Humalog Kwikpen U-100Insulin Lispro13$2,624
Wixela InhubFluticasone Propion/Salmeterol12$2,334
Metoprolol Succinate142$1,972
Levothyroxine Sodium190$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$24$58,63546 claims
Novo NordiskOzempic$74$54,82436 claims
Lilly USA, LLCTrulicity$38$22,34012 claims
Johnson & JohnsonXarelto$29$20,75018 claims
AstraZenecaFarxiga$120$12,89012 claims
GSKBreo Ellipta$31$7,15012 claims
AbbVieSynthroid$12$1,44617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →